Moderate-to-late prematurity: understanding respiratory consequences and modifiable risk factors
- PMID: 40500129
- PMCID: PMC12152585
- DOI: 10.1183/16000617.0267-2024
Moderate-to-late prematurity: understanding respiratory consequences and modifiable risk factors
Abstract
As survival rates of preterm infants have increased due to advances in perinatal care, focus has shifted towards the profound long-term effects of prematurity. An extensive amount of evidence has shown increased susceptibility to chronic illnesses among preterm infants. While the onset of such conditions typically emerges during adulthood, their roots trace back to the early stages of life. Much of this interest has been directed towards short- and long-term consequences of extreme and very preterm birth. However, it has become apparent that, despite a limited risk of complications during the neonatal period, the moderate and late preterm population suffers from an increased likelihood of morbidity during the course of life. Considering the higher prevalence of moderate and late preterm births compared to extreme and very preterm births, understanding and investigating their health outcomes is essential to address the broader impact of prematurity. In this review, we will discuss the impact of moderate and late prematurity on lung development, function and how environmental factors impose these individuals to increased risk for respiratory morbidity during the course of life. We describe interventions during early life that may protect the moderate-to-late preterm population from adverse lung development and further deterioration by addressing modifiable risk factors.
Copyright ©The authors 2025.
Conflict of interest statement
Conflict of interest: All authors report having no ethical or financial conflicts of interest related to this manuscript. K.D. Tsang reports support for the present study from BeterKeten. G.A. Tramper-Stranders reports grants from OM Pharma and AstraZeneca, participation on a data safety monitoring board or advisory board with GINSBY trial, and a leadership role with EAACI as chair of the task force on Conscious and rational use of antibiotics in allergic diseases. J.V. Been reports grants from Chiesi Pharmaceuticals. A.K. Hoffmann-Haringsma, I.K. Reiss, M.W.H. Pijnenburg and I.M. De Kleer have nothing to disclose.
Figures
References
-
- Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012; 379: 2162–2172. doi: 10.1016/S0140-6736(12)60820-4 - DOI - PubMed
-
- Fisher PG. Prematurity is a chronic disease. J Pediatr 2022; 246: 1–3.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials